ERBB2 and breast carcinoma: Collectively, these results show that PIs potently decrease HER2 phosphorylation and activity, thereby attenuating downstream signaling pathways such as PI3K/Akt and Ras/MAPK that confer endocrine therapy resistance and estrogen-independence in ER+ breast cancer [18, 19].